dc.contributor.author | Lopez-Knowles, E | |
dc.contributor.author | Detre, S | |
dc.contributor.author | Hills, M | |
dc.contributor.author | Schuster, EF | |
dc.contributor.author | Cheang, MCU | |
dc.contributor.author | Tovey, H | |
dc.contributor.author | Kilburn, LS | |
dc.contributor.author | Bliss, JM | |
dc.contributor.author | Robertson, J | |
dc.contributor.author | Mallon, E | |
dc.contributor.author | Skene, A | |
dc.contributor.author | Evans, A | |
dc.contributor.author | Smith, I | |
dc.contributor.author | Dowsett, M | |
dc.date.accessioned | 2022-09-14T08:31:55Z | |
dc.date.available | 2022-09-14T08:31:55Z | |
dc.date.issued | 2022-09-12 | |
dc.identifier.citation | Breast Cancer Research, 2022, | |
dc.identifier.issn | 1465-542X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5467 | |
dc.description.abstract | BACKGROUND: In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO/CAP recommends cut-offs of < 1% (negative) and 1-10% (low) cells positive. There is uncertainty whether patients with ER low tumours benefit from endocrine therapy. We aimed to assess IHC and mRNA cut-points for ER versus biological response of primary breast cancer to 2 weeks' aromatase inhibitor treatment as measured by change in Ki67. METHODS: Cases were selected from the aromatase inhibitor treatment group of POETIC. We selected the 15% with the poorest Ki67 response (PR, < 40% Ki67 suppression, n = 230) and a random 30% of the remainder categorised as intermediate (IR, 40-79% Ki67 suppression, n = 150) and good-responders (GR, ≥ 80% Ki67 suppression, n = 230) from HER2 - group. All HER2 + cases available were selected irrespective of their response category (n = 317). ER expression was measured by IHC and qPCR. RESULTS: ER IHC was available from 515 HER2 - and 186 HER2 + tumours and ER qPCR from 367 HER2 - and 171 HER2 + tumours. Ninety-one percentage of patients with ER IHC < 10% were PRs with similar rates in HER2 - and HER2 + cases. At or above ER IHC 10% substantial numbers of patients showed IR or GR. Similar proportions of patients were defined by cut-points of ER IHC < 10% and ER mRNA < 5 units. In addition, loss of PgR expression altered ER anti-proliferation response with 92% of PgR - cases with ER IHC < 40% being PRs. CONCLUSIONS: There was little responsiveness at IHC < 10% and no distinction between < 1% and 1-10% cells positive. Similar separation of PRs from IR/GRs was achieved by IHC and mRNA. | |
dc.language.iso | eng | |
dc.publisher | BMC | |
dc.relation.ispartof | Breast Cancer Research | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-08-27 | |
dc.date.updated | 2022-09-14T08:18:59Z | |
rioxxterms.version | VoR | |
rioxxterms.licenseref.startdate | 2022-09-12 | |
rioxxterms.type | Journal Article/Review | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.publication-status | Published online | |
icr.researchteam | Molecular Oncology | |
dc.contributor.icrauthor | Lopez Knowles, Elena | |
dc.contributor.icrauthor | Schuster, Eugene | |
dc.contributor.icrauthor | Cheang, Chon | |
dc.contributor.icrauthor | Tovey, Holly | |
dc.contributor.icrauthor | Kilburn, Lucy | |
dc.contributor.icrauthor | Bliss, Judith | |
icr.provenance | Deposited by Dr Elena Lopez Knowles on 2022-09-14. Deposit type is initial. No. of files: 1. Files: ER low Manuscript Resubmission Clean 17.08.22.docx | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Dr Elena Lopez Knowles) on 2022-09-14. Deposit type is subsequent. No. of files: 1. Files: s13058-022-01556-6.pdf | |